ABSTRACT
We have conducted for the first time an experimental study of pharmacokinetics of dicholine succinate (DCS) for different ways of its administration in rats The quantitative evaluation of DCS and its metabolites was performed by the radioactive isotope technique. Various parameters of DCS pharmacokinetics were estimated, including the dose dependence of drug content in the blood plasma, total bioavailability, distribution kinetics, and the main ways of DCS excretion.
Subject(s)
Choline/analogs & derivatives , Hypoglycemic Agents/pharmacokinetics , Nootropic Agents/pharmacokinetics , Pipecolic Acids/pharmacokinetics , Succinates/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Choline/blood , Choline/pharmacokinetics , Choline/urine , Feces/chemistry , Hypoglycemic Agents/blood , Hypoglycemic Agents/urine , Male , Nootropic Agents/blood , Nootropic Agents/urine , Pipecolic Acids/blood , Pipecolic Acids/urine , Rats , Succinates/blood , Succinates/urine , Tissue Distribution , TritiumABSTRACT
The anticonvulsant effect of dicholine succinate (DCS), a neuronal insulin sensitizer, has been studied on two models of primary generalized epilepsy induced by corazole and maximal electroshock (ME) in mice. It has been found that DCS administered intraperitoneally for 7 days in a dose of 10 mg/kg produces a significant anticonvulsant effect on the model of corazole-induced seizures. The drug increases the latency of corazole-induced seizures, changes the character of seizures, and increases lifespan of animals, while not protecting against loss. At the same time, DCS does not exhibit any effect on ME-induced seizures.
